Beyond the Pill: A Topical Solution for Arthritis Pain?

SUMMIT, N.J. – April 01, 2026 – For the millions of adults worldwide whose daily lives are constrained by the chronic pain of knee osteoarthritis, relief often comes in the form of a pill with a long list of potential side effects. A new development from pharmaceutical company Vascarta Inc., however, suggests a promising alternative may be on the horizon—one that is applied directly to the skin.

The company has announced positive results from a clinical trial for VAS-101, an investigational topical gel that uses curcumin, the active compound in turmeric, as its key ingredient. The study, published in the peer-reviewed journal Frontiers in Pain Research, demonstrated that the gel significantly reduced knee pain in participants with osteoarthritis compared to a placebo, marking a potential step forward in managing the debilitating condition.

A New Approach to an Old Problem

Knee osteoarthritis is a degenerative joint disease characterized by the breakdown of cartilage, leading to pain, stiffness, and reduced mobility. While numerous treatments exist, they often present a trade-off between efficacy and safety. Oral non-steroidal anti-inflammatory drugs (NSAIDs) can cause gastrointestinal and cardiovascular issues, while other options may offer insufficient relief.

Vascarta’s Phase 1b trial was designed to test a different approach. The randomized, double-blind, placebo-controlled study enrolled 60 adults aged 45 to 75. Participants applied a small amount of either VAS-101 or a placebo gel to their affected knee every other day for 28 days. The results were statistically significant. Those using VAS-101 showed a meaningful improvement on the Knee injury and Osteoarthritis Outcome Score (KOOS) pain subscale, the study's primary endpoint. They also reported a significant reduction in daily pain ratings.

Crucially, the improvements were not just statistically significant but clinically meaningful for many. Nearly 40% of participants in the VAS-101 group reported feeling "much improved" or "very much improved," a figure almost three times higher than the 13.3% reported in the placebo group. The treatment was also well-tolerated, with no significant adverse reactions. The only notable side effect was temporary, localized skin staining, a known characteristic of curcumin that resolved within a few days of discontinuing use.

"The results of this study demonstrate that, in people with knee osteoarthritis, the topical application of VAS-101 reduced knee pain within 28 days, with clinically meaningful improvements occurring in approximately 40% of participants," stated Dr. Adrian Lopresti, the study's principal investigator and Managing Director of Clinical Trials Australia. "VAS-101 may represent a promising option for individuals experiencing knee osteoarthritis."

Unlocking Curcumin's Potential

The use of curcumin for its anti-inflammatory properties is not new; it has been a staple of traditional medicine for thousands of years. Modern science has validated its ability to inhibit key inflammatory pathways, such as NF-κB and COX-2, which are directly involved in the pain and swelling of arthritis. However, its translation into a mainstream pharmaceutical has been hampered by a major biological hurdle: poor oral bioavailability. When consumed, curcumin is poorly absorbed, rapidly metabolized by the liver, and quickly eliminated from the body, meaning very little of the active compound reaches the target tissues.

Vascarta's innovation lies in its proprietary transdermal delivery technology, which is designed to bypass these limitations entirely. The VAS-101 gel delivers curcumin directly through the skin to the affected joint. This localized approach avoids the gastrointestinal tract and first-pass liver metabolism, allowing for a higher concentration of the anti-inflammatory compound at the site of pain while minimizing systemic exposure and associated side effects.

"While further research with larger patient populations and longer treatment durations is needed, these findings highlight the potential role of VAS-101 in managing osteoarthritis pain," said Joel Friedman, M.D., Ph.D., the inventor of Vascarta's patented technology and the company's Chief Scientific Officer. The Professor Emeritus at Albert Einstein College of Medicine added that this approach may offer a promising non-oral therapeutic strategy for managing the condition.

The Road to Approval and Beyond

The positive data represents a critical milestone for Vascarta as it seeks to carve out a place in the vast osteoarthritis treatment market. The company has announced its intention to file an Investigational New Drug (IND) Application with the U.S. Food & Drug Administration (FDA) later this year. An IND filing is the formal step required to begin larger and more rigorous clinical trials (Phase 2 and 3), which are necessary to confirm the drug's safety and efficacy in hundreds or thousands of patients before it can be considered for market approval.

This move positions VAS-101 as a potential disruptor in a field with significant unmet needs. Patients and clinicians are actively seeking effective, long-term pain management solutions that avoid the risks of systemic medications and reduce reliance on opioids. A safe, effective, and easy-to-use topical gel could fill that void.

"These data indicate the potential of VAS-101 to become the standard of care in osteoarthritis," said Vascarta's Chairman and CEO, Richard Prince, Ph.D. "We intend to accelerate our efforts in the development of VAS-101 for osteoarthritis."

The company's ambitions for its delivery platform extend beyond knee pain. The technology's versatility has already been recognized by the FDA, which granted Orphan Drug Designation to VAS-101 for the treatment of Sickle Cell Disease, another condition driven by inflammation and pain. This suggests the platform could potentially be used to deliver other therapeutic compounds for a range of diseases. With a clear regulatory path ahead for its lead candidate and a technology platform showing broad potential, the journey for VAS-101 from a promising compound to a staple in pain management is one the medical and patient communities will be watching closely.